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ABSTRACT 
 
 
Splenomegaly is frequently found in non-Hodgkin’s lymphoma (NHL) patients. This study evaluated the 
implications of splenic volume change in response to radioimmunotherapy (RIT). Methods: Twenty-nine 
NHL patients treated with radiolabeled-Lym-1 and 9 breast cancer patients (reference group) treated with 
radiolabeled-ChL6, BrE-3 or m170 were analyzed using CT splenic images obtained before and after 
RIT. Patient-specific radiation doses to spleen were determined using actual splenic volume determined 
by CT and body weight. Results: In 13 of 29 NHL patients who had splenic volume £310 ml, there was 
no or small change (-23 to 15 mL) in splenic volume, despite splenic doses as high as 14.4 Gy.  Similarly, 
in a reference group of 9 breast cancer patients, there was no or small change (-5 to 13 mL), despite 
splenic doses as high as 11.4 Gy. In contrast, 13 of 29 NHL patients who had splenic volume 380-1400 
mL, splenic volume decreased by 68 to 548 mL despite splenic doses as low as 1.40 Gy. Ten of 29 NHL 
patients with greater than a 15% decrease in splenic volume after RIT had nodal tumor regression (5 CR, 
5 PR). In the remaining 19 NHL patients with less than a 15% decrease in splenic volume after RIT, there 
were 7 non-responders (5 CR and 7 PR). Conclusion: Splenic volume changes were found in NHL 
patients with splenomegaly. These splenic volume changes is likely due to therapeutic effect on malignant 
lymphocytes associated with splenomegaly. Nodal tumor response was more likely when splenomegaly 
decreased after RIT.  
Key Words: Splenomegaly, Radioimmunotherapy, Radiation dosimetry, Lymphoma, Cancer therapy. 
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INTRODUCTION 
 
 
 Splenomegaly occurs frequently in non-Hodgkin’s lymphoma (NHL) patients as a result of NHL 
infiltration. Associated hypersplenism can cause anemia which needs frequent transfusions, as well as 
increased susceptibility to infection and bleeding. For radioimmunotherapy (RIT), an enlarged spleen can 
represent a “sink” to take a large portion of radiolabeled antibody before it is available for nodal tumors. 
Although splenomegaly is not classified as a tumor burden (1), an enlarged spleen with malignancy is 
generally associated with poor prognosis. Patients with splenomegaly have been excluded from trials of 
radioimmunotherapy because they, in general, did not have a "favorable biodistribution" reflected by 
lower tumor uptake (2,3). However, in treatment of NHL with 131I-Lym-1, although a positive correlation 
was found between splenic volume and splenic cumulated activity, no correlation was found between 
initial splenic volume and nodal tumor response (4). Complete response occurred in a patient whose 
spleen was 970 ml, while there were two non-responders and four partial responders among six patients 
who had prior splenectomy. Similarly, no correlation was found between splenomegaly and nodal tumor 
response in NHL patients receiving with 90Y-IDEC-Y2B8 (5). 
 Although the rationale for excluding patients with splenomegaly from RIT has not been clearly 
supported by clinical evidences, the benefit of treating patients with splenomegaly has also not been 
established. Uptake of radiolabeled antibody by an enlarged spleen might be therapeutic for malignant 
lymphocytes in the spleen. Because we treated patients with splenomegaly, we were able to examine the 
implications of splenomegaly and change in splenic volume due to RIT. In the present study, changes in 
splenic volume were examined in NHL patients with and without splenomegaly. As an additional point of 
comparison, we also measured the spleen sizes of a reference patient group (breast cancer patients) before 
and after RIT, whose spleen are expected with no malignant involvement. A practical patient-specific 
splenic dosimetry method was used to account for large deviation for actual spleen volume and body 
weight from that of reference man (6,7). 
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MATERIALS AND METHODS 
 
Radiopharmaceuticals 
 131I-Lym-1 and 67Cu-2IT-BAT-Lym-1. Lym-1 is an IgG2a, mouse monoclonal antibody (MAb) with 
high affinity for a polymorphic variant of the HLA-DR membrane antigen found on B-cell malignancies 
(8).  Iodine-labeled Lym-1 was prepared using chloramine T at a mass ratio of about 1 mg chloramine 
T:10 mg Lym-1. Copper-labeled Lym-1 was conjugated with 2IT-BAT for labeling with 67Cu (9). 
131I-ChL6 and 131I-L6.  ChL6 is an IgG1 humanized MAb that binds to adenocarcinomas, including 
50% of human breast cancer. ChL6 also mediates antibody-dependant cytotoxicity (10). The 
radiopharmaceuticals were prepared by chloramine T radioiodination with 131I and contained 10 mCi 
131I/mg antibody and 1 mCi 131I/ml solution. 
111In/ 90Y-MX-DTPA-Bre-3. Bre-3 is a mouse IgG1 MAb that recognizes an epitope on the tandem 
repeat of the peptide core of breast mucin (11). Bre-3 binds to 97% of human ductal breast cancer 
specimen. Bre-3 was provided by Coulter Immunology and conjugated with MX-DTPA for labeling with 
111In and 90Y. 
111In/ 90Y-2IT-BAD-m170. m-170 is a panadenocarcinoma MAb that reacts with over 90% of human 
adenocarcinomas, including breast cancers (12). m-170 was provided by Biomira (Canada) and 
conjugated with 2IT-BAD for labeling with 111In and 90Y. 
 
Patients  
 Inclusion Criterion. Spleen volume was determined from CT images. All patients had CT scans 
before and after RIT, however, in some patients, CT films did not completely cover the spleen volume as 
these films were prepared previously for the purpose of tumor assessment. In the current retrospective 
analysis, patients were excluded if they did not have complete CT information for spleen volume 
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measurements before and after RIT. 
 NHL patients. At the time of this analysis, 66 NHL patients received 131I-Lym-1 (n=54) (13,14), or 
67Cu-2IT-BAT-Lym-1 (n=12) (9,15). All patients had failed combination chemotherapy. Within this 
group, 29 patients (25 received 131I, 4 received 67Cu) were included because they had abdominal CT films 
that covered spleen volume before and after RIT (Table 1). Splenic volume change in response to RIT 
was examined. 
 Breast cancer patients. At the time of this analysis, 16 breast cancer patients received 131I-ChL6, 131I-
L6 (n=11) (10), 90Y-MX-DTPA-Bre-3 (n=4) (11), or 90Y-2IT-BAD-m170 (n=1) (12). All patients had 
failed combination chemotherapy for metastatic diseases. Within this group, 9 patients (6 received 131I, 3 
received 90Y) were included because they had abdominal CT films that covered spleen volume before and 
after RIT (Table 1). These breast cancer patients served as a reference group for splenic volume change of 
in response to RIT. 
All patients were signed an informed consent for the protocol that was approved by the University of 
California at Davis Human Subjects and Radiation under an Investigational New Drug authorization from 
the US Food and Drug Administration. 
 
Splenic Volume and Nodal Tumor Response Assessment 
 Splenic volume assessment. All patients in the present analysis received multiple doses of RIT (Table 
1). The time intervals between the doses were 2 or 4 weeks (9-16). CT scans were acquired 1-3 weeks 
before RIT, and at least 2 weeks after the last dose of RIT. The average time interval between the last 
dose injection and the after treatment CT scan was 5 weeks in breast cancer patients and 4 weeks in NHL 
patients. Transverse CT slices were either 5 or10-mm in thickness. Splenic volumes were determined 
using the sum-of-areas method (4,17). The area of spleen region of interest (ROI) on each CT slice was 
determined by a digitizer and multiplied by the slice thickness to obtain the spleen volume in each slice. 
All slices were summed to determine the total spleen volume. The accuracy of this method was 3.6 ± 
4.5% (17). A 15% volume change (> 2s) after RIT was considered as substantial with a confidence level 
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high than 98%. Based on definitions by Goldstone (18) and Xiros et al. (19), a splenic volume ³ 1500 mL 
is considered as massive splenomegaly, a volume of 500-1499 mL is considered as moderate 
splenomegaly. 
 For assessing possible splenic volume change during sequential planar imaging, splenic sizes were 
measured using planar images.  Ten lymphoma patients who had > 15% CT volume change after RIT 
were assessed as splenic volume changes during sequential planar imaging were more likely to be 
detected in those patients. Splenic sizes were measured in the long axis L and the perpendicular short axis 
W of the spleen silhouette as visualized in planar images acquired immediately and ³ 120 hours post 
injection. This approach follows the method described Silverman et al. (20), which demonstrated that 
spleen size can be estimated from measurements of length and width of the spleen as visualized by a 
gamma camera after administration of technetium-99m sulfur colloid, with a 1-standard-deviation 
accuracy of 45g. 
 Nodal tumor response assessment. Nodal tumors were evaluated by CT or MRI, except for small 
palpable tumors (14). Nodal tumor masses were evaluated by CT or MRI at a minimum of 1 and 3 
months after completion of RIT, and then at a 6-month interval. For small palpable tumors, two 
perpendicular diameters for each mass were measured using a caliper at each physical examination. 
Tumor responses were classified as complete response (CR), the complete absence of demonstrable 
disease, including negative bone marrow examination, or partial response (PR), a decrease in the sum of 
the products of all tumor dimensions by at least 50% or all tumor volumes by at least 70%. The remaining 
patients were classified as non-responder (NR). 
 
Radiation Dosimetry 
 Planar image quantification for the spleen has been previously described (4,21,22). Briefly, planar 
conjugate views for whole body and abdomen were acquired with a Siemens Bodyscan dual-head camera 
or an Orbitor single-head camera (Siemens Medical System, Inc., Des Plaines, IL). A high-energy 
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collimator was used for 131I and a medium energy collimator was used for 67Cu and 111In. Serial images of 
conjugate views were acquired immediately, 4-6 hours and daily up to 144-264 hours post administration 
of radiolabeled antibodies. All sequential images were displayed for selecting one image that had best 
image contrast for spleen. A single reference spleen ROI was determined from that image and this single 
ROI was mapped to the spleen in all sequential images. The amount of radioactivity in spleen and body 
were determined by converting counts in spleen and body ROI using geometric-mean quantification. 
Cumulated activity and biological half-life of the spleen and body were determined by fitting 
pharmacokinetic data to a mono-exponential curve. Cumulated 90Y activity was derived from that of 111In 
assuming they had identical uptakes (11). 
 For an effective clearance half-life of 18 hour (23), 99% of the radiation dose to the spleen was 
absorbed within 120 hours post injection. There was no or small spleen size change during sequential 
planar imaging (see Results), spleen volume was considered as a constant or adjusted for a measured 
small change in dose calculation. Radiation dose to spleen was calculated using a practical, patient-
specific approach (24) 
)()~~()(~ RBspleenSAAspleenspleenSAD spleenTBspleenspleen ¬×-+¬×=    Eq.1 
where Ãspleen and ÃTB  were cumulated radioactivity in spleen and total body; S(spleen¬spleen) and 
S(spleen¬RB) were S values from spleen to spleen and from the remainder of the body to spleen. 
S(spleen¬RB) equals zero for the pure beta emitter, 90Y (6). For 131I and 67Cu (25) 
 
RB
spleen
RB
TB
m
m
spleenspleenS
m
mTBspleenSRBspleenS ×¬-×¬=¬ )()()(    Eq. 2 
where mTB was the patient-specific body weight; mspleen was determined from the CT volume assuming 1 
g/mL; mRB was the difference between mTB and mspleen; S(spleen¬TB) was S value from total body to 
spleen. Patient-specific S(spleen¬TB) was calculated as 1.07×S(TB¬TB) for 131I and 1.04×S(TB¬TB) 
for 67Cu (see last paragraph of DISCUSSION). Patient-specific S(TB¬TB) was calculated according to 
MIRD schema (26): 
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TBTBS f      Eq. 3 
where Dp and Dnp were equilibrium dose constant for each penetrating (p) and non-penetrating (np) 
radiation energy; fp(TB¬TB) was the absorbed fraction for each penetrating radiation energy for the total 
body. The value of fp(TB¬TB) for each photon energy was calculated with logarithmic interpolation of 
listed photon energies (20- 2750 keV) and body masses (40-200 kg) in the MIRD table (27,28). Similarly, 
patient-specific S(spleen¬spleen) was calculated as: 
 ])([1)( åå D+¬×D×=¬ nppp
TB
spleenspleen
m
spleenspleenS f    Eq. 4 
where the value of fp(spleen¬spleen) for each photon energy was calculated with logarithmic 
interpolation of listed photon energies (20 – 2750 keV) and target masses (40- 6000 g) in MIRD tables 
(27-29). The above computations were implemented using a software program developed in-house on a 
PC computer. 
 
 
RESULTS 
 
Splenic Volume Change and Nodal Tumor Response 
 Splenic volume changes after RIT were found in the NHL patients. Although there was no correlation 
between splenic volume change and radiation absorbed dose to the spleen, splenic volume changes was 
more likely in patients with enlarged spleen (Fig 1). In 13 of 29 NHL patients who had initial splenic 
volumes of 150-310 ml, splenic volume changed 0% (range –9 to 7%) despite radiation doses to the 
spleen as large as 11.4 Gy (Table 2). Similarly, in 9 breast cancer patients who had initial splenic volume 
of 70-340 mL, splenic volume changed 0% (range –4 to 5%) despite radiation doses to the spleen as large 
as 14.4 Gy. In contrast, in the 13 of 29 NHL patients who had spleens volume of 380-1400 ml, splenic 
volumes decreased by 28% (range 12-57%) after receiving a splenic dose as low as 1.40 Gy. In the 
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remaining 3 NHL patients who had initial splenic volume of 340-700 mL, splenic volume increased by 8, 
10 and 220% after RIT. The patient with 220% splenic volume increase had progressive tumor growth 
after RIT (non-responder).  
  There was no clear relationship between tumor response and initial splenic volume. However, 
tumor response was more likely in those patients with greater splenic volume decrease after RIT (Fig 2). 
Ten of 29 NHL patients with > 15% splenic volume decrease all had nodal tumor regression (5 CR, 5 
PR). In the remaining 19 NHL patients with < 15% splenic volume decrease, there were 7 non-responders 
(5 CR, 7 PR).  
 
Radiation Dosimetry 
 In 10 of 29 NHL patients who had splenic CT volume change > 15%, mean splenic volume change 
during sequential imaging were 3.8% (range –2.9 to 10.2) (Table 3). Although 144 hour was the last 
imaging time point for patient No.9, image at day 72 hours post injection was used for splenic volume 
measurement as spleen image contrast became poor after 96 hours. This patient had effective clearance 
half life of 15.5 hour for the spleen, 96% radiation dose was deposited to the spleen during 72 hours. 
Spleen volume was adjusted by 3.5% (an average for 7.0%) for patient 3, 3.7% for patient 4, 4.4% for 
patient 7, and 5.1% for patient 8. For the remaining 25 NHL patients, splenic volume was considered to 
be constant in splenic dose calculation. 
 Splenic volume ranged from 140 to 2240 mL in 29 NHL patients and from 70 to 340 mL in 9 breast 
cancer patients (Table 4). Consequently, the calculated radiation dose to spleen using the 
S(spleen¬spleen) values from  MIRD reference  man  (174 g)(6) would be underestimated or 
overestimated for individual patients. The patient-specific S(spleen¬spleen) value decreased as the 
spleen mass increased (Fig 3.). In 25 NHL patients that received 131I-Lym-1, spleen dose contribution 
from radioactivity in spleen would have been overestimated by a factor of 10 if the S(spleen¬spleen) 
value from MIRD reference man was used for a patient whose spleen volume was 2240 mL.  
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 As a secondary but still significant effect, body weights ranged from 49 kg to 146 kg in 29 NHL and 
9 breast cancer patients (Table 3). The calculated radiation dose to body, using the S(TB¬TB) values 
from  MIRD mathematical phantom of reference man (69.88 kg)(6), would be underestimated or 
overestimated for individual patients. Patient-specific S(TB¬TB) value decreased as body weight 
increased. In 25 NHL patients that received 131I-Lym-1, deviation in body dose ranged from 27% 
underestimation for a patient who weighed 49 kg to 96% overestimation for a patient who weighed 146 
kg, if the S(TB¬TB) values of MIRD phantom were used. 
 
 
DISCUSSION 
   
 The spleen consists of red pulp (containing abundant erythrocytes and venous sinuses), white 
pulp (containing mainly lymphocytes), and connective tissues. As erythrocytes, venous sinuses, and 
connective tissues are relatively radiation-resistant, only white pulp in spleen is radiation-sensitive. In the 
present analysis, we observed in 13 NHL patients who had splenic volumes of 150-310, the change in 
splenic volume ranged –9 to 7% despite radiation dose to spleen as high as 11.4 Gy (Table 2). Similarly, 
in a reference group of 9 breast cancer patients who had initial splenic volume of 70-340 mL, splenic 
volume changed–4 to 5%, despite radiation doses to the spleen as large as 14.4 Gy. These observations 
are in agreement with other reports of no measurable change in splenic size (30) and functional 
impairment (31) for dose up to 18 Gy. All these observations are consistent with the fact that the 
radiosensitive white pulp represents only a small portion of total splenic volume (white pulp represents 
6.3-8.3 % of the reference adult spleen)(32). 
 Splenic volume changes after RIT were found in NHL patients who had enlarged spleens, a 
condition wherein NHL involvement is more likely. In 28 NHL patients who had a spleen mass greater 
than 500 g and underwent splenectomy, Xiros et al found 27 patients (96%) had spleen NHL involvement 
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(19). In the present study, 13 of the 29 NHL patients with spleen volume of 380-1400 ml had splenic 
volume decreases by 70-550 mL associated with a low splenic dose (Table 2). Differential results in 
normal-sized and enlarged spleens suggests that the decrease in splenic volumes after RIT in the above 
dose range is likely due to therapeutic effect on malignant lymphocytes associated with splenomegaly. 
Because an enlarged spleen commonly represents a poor prognostic indicator of itself, splenectomy is 
often performed in NHL patients with substantial splenomegaly. For patients without splenectomy, a 
large splenic uptake of radiolabeled antibody is therapeutic for malignant lymphocytes in the spleen. This 
is consistent with the treatment of chronic lymphocytic leukemia (CLL) and Hodgkin’s lymphoma using 
external bean radiotherapy (33). 
 In the 13 NHL patients that had initial spleen volume of 380-1400 mL, 13 patients showed 
splenic volume decrease after RIT (Table 2). However, the remaining 3 patients had splenic volume 
increase after receiving a relative low radiation dose to the spleen (1.0-3.5 Gy). Two of them showed 
splenic volume increase of 8% and 10% were partial-responders (PR). The third patient, who had 220% 
increase in splenic volume, was a non-responder (NR). This is consistent with the general observation that 
tumor response was more likely in patients with splenic volume decrease (Fig 2).  
  The use of MIRD S values based on population-averaged organ masses (mathematical phantom 
of reference man) provides a convenient approach for computation of radiation dose for individual 
patients. However, the use of fixed organ dimensions can introduce substantial deviation in radiation dose 
estimates as organ size can vary substantially among patients. Accurate dosimetry requires patient-
specific organ mass. Using the sum-of areas method for CT sections of 10-mm thickness, Breiman et 
al(17)  reported a mean error of 4.95 % (± 2.61%) for phantoms ranging from 200 to 1000 ml, and a mean 
error of 3.59 % (± 4.5%) for 8 spleens ranging from 309 to 3675 ml. Furthermore, Breiman et al found a 
mean error of 3.65% for these patients using CT scan at 20-mm slice thickness, suggesting that the 
problem of partial volume was not significant for spleen at 20-mm slice thickness(17).  As CT slices in 
the present study were either 5 or 10-mm thickness, the accuracy of spleen volume measurement should 
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be comparable to that of Breiman et al. 
  Patient-specific dosimetry is best calculated using Monte Carlo or dose-kernel convolution 
techniques based on CT and SPECT data(34-36). These techniques are not now generally available at 
clinical sites. One of the difficulties in patient-specific dose calculation is to estimate photon dose 
contribution from other source organs without a 3-D data set. One practical solution is to include all 
source organs other than the target (spleen) in the remainder of the body(27). First, in 59 lymphoma 
patients receiving 131I or 67Cu, the deviation introduced by including all sources other than spleen in the 
remainder of the body was inconsequential (mean 0.2%, range 0.0-0.6%)(27). Therefore, the task of 
S(target¬other source) computation was simplified to S(spleen¬TB) computation (Equation 2). Second, 
despite the large mass difference between liver, spleen and kidneys, the MIRD values for S(spleen¬TB), 
S(liver¬TB) and S(kidneys¬TB) are almost identical for 131I and 67Cu(6,7). Therefore, S(spleen¬TB) 
value is not sensitive to the spleen mass but is sensitive to body mass. Third, despite the large mass 
difference between the adult phantom of 70 kg weight, the child phantom of 58 kg weight and the child 
phantom of 15 kg weight, the ratio of S(spleen¬TB) value to S(TB¬TB) value were all about 1.07 for  
131I and 1.04 for 67Cu(7). As S(spleen¬TB) can be calculated as 1.07 S(TB¬TB) for 131I and 1.04 
S(TB¬TB) for 67Cu, the task of patient-specific S(target ¬other source) computation becomes patient-
specific S(TB¬TB) computation that can be readily calculated using Equation 3. 
 
  
CONCLUSION 
 
  Splenic volume changes were found in lymphoma patients with enlarged spleen. The decrease in 
splenic volume after RIT seemed related to therapeutic effect on malignant lymphocytes associated with 
splenomegaly. Nodal tumor response was more likely in those NHL patients with greater splenic volume 
decrease after RIT. RIT seems benefit to NHL patients with splenomegaly. 
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Table 1 
29 non-Hodgkin’s lymphoma and 9 breast cancer patients* had CT abdomen images before and after radioimmunotherapy. 
Radiopharmaceuticals Disease 
 
Number of 
Patients 
 
Number of 
doses/patient 
(range) 
Range of total 
radioactivity/patient  
(GBq) 
 
131I-Lym-1 
 
NHL 
 
25 
 
1-13 
 
1.74- 27.16 
 
 
67Cu-2IT-BAT-Lym-1 
 
NHL 
 
4 
 
2-3 
 
3.74-6.55 
 
 
90Y-MX-DTPA-BrE 3 or 
90Y-2IT-BAD-m170 
 
Breast cancer 
 
3 
 
1-3 
 
0.41-2.00 
 
 
131I-ChL6/L6 
 
Breast cancer 
 
6 
 
2-3 
 
6.25-30.90 
 
 
*: As a reference group. Spleens are expected to be no malignancy involved.  
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Table 2. Splenic volume change in response to RIT. 
 
Patients Initial splenic volume 
(ml) 
Mean (range) splenic 
dose (Gy) 
Mean (range) volume 
change after RIT (mL) 
16 NHL patients 
13 NHL 
 
3 NHL 
 
 
380 to 1400 
340 to 700 
 
3.6 (1.1 to 7.0) 
 
2.2 (1.0 to 3.5) 
 
-186 (-68 to -548) 
 
542 (35 to 1535) 
13 NHL patients 150 to 310 8.0 (1.2 to 11.4) -2 (-23 to 15)  
9 breast cancer* 70 to 340 11.5 (1.9 to 14.4) 1 (-5 to 13) 
 
*: As a reference group. Spleens are expected to be no malignancy involved. 
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Table 3. Planar image assessment for splenic volume change during sequential planar imaging.  
10 NHL patients who had CT spleic volume change >15% were assessed. 
 
NHL Patients Duration of sequential 
imaging 
Planar splenic volume  
change (%) 
No.1 
No.2 
No.3 
No.4 
No.5 
No.6 
No.7 
No.8 
No.9 
No.10 
Immediate-264 hr 
Immediate-240 hr 
Immediate-144 hr 
Immediate-144 hr 
Immediate-144 hr 
Immediate-144 hr 
Immediate-144 hr 
Immediate-144 hr 
Immediate-72 hr* 
Immediate-120 hr 
2.9 
3.4 
7.0 
7.3 
2.5 
-2.9 
8.7 
10.2 
2.4 
5.5 
 
*: Image contrast was poor after 96 hours. During 72 hours, 96% of radiation dose was deposited to the spleen. 
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Table 4 
Mass and patient-specific absorbed dose for total body and spleen. 
Treatment study  Mean (range) body 
weight in kg 
Mean (range) body 
absorbed dose in 
Gy/GBq  
Mean (range) splenic 
volume in ml before 
RIT 
Mean (range) splenic 
absorbed dose in 
Gy/GBq  
90Y-MX-DTPA-BrE3 or 
2IT-BAD-m170 
56.8 (50.7-68.2) 0.69 (0.58-0.84) 
 
150 (70-320) 4.67 (2.16-6.29) 
131I-ChL6/L6 65.4 (52.7-80.8) 0.24 (0.13-0.33) 
 
230 (130-340) 0.88 (0.47-1.36) 
131I-Lym- 1 81.4 (49-146) 0.10 (0.05-0.22) 
 
420 (140-2240) 0.53 (0.16-1.91) 
67Cu-2IT-BAT-Lym-1 84 (70-92) 0.09 (0.08-0.10) 630 (160-1340) 0.65 (0.25-1.05) 
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Figure Legend 
Figure 1. In the 29 NHL patients, splenic volume change after RIT was more likely in patients with 
enlarged spleen.  
 
Figure 2. In the 29 NHL patients, nodal tumor response was more likely in those patients with 
greater splenic volume decrease after RIT.  
 
Figure 3. Patient-specific S(spleen¬spleen) value (rad/mCi-hr) in 25 NHL patients receiving 131I-
Lym-1 (Equation 4). Substantial deviation from the actual spleen to spleen dose would be 
introduced if a fixed S(spleen¬spleen) value of 2.6 x 10-3 (rad/mCi-hr) from MIRD No. 
11 or 2.57 x 10-3 (rad/mCi-hr) from MIRDOS III program based on MIRD spleen 
phantom of 173.6g were used. 
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Fig 1 
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Fig 2 
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Fig 3 
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